ARQULE INC (ARQL)

Overview Price 7.87 Price Change Today 0.00 (0.00%) P&P rating Zacks Rank 3 - HOLD Open Price $0.00 Previous Close $7.87 Daily Range $0.00 - $0.00 52-Week Range $3.98 - $8.19 Volume 0 ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche. Other Resources for ARQL Detailed Quote Earnings Estimates Company Report Interactive Chart Commentary Zacks Blog: Company News for January 18, 2012 January 18, 2012 Zacks Blog: Zacks #1 Rank Additions for Tuesday November 15, 2011 Zacks Blog: Zacks #1 Rank Additions for Tuesday October 4, 2011 ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.   Brokerage Analyst Recommendations 5 Brokerage Firms Covering ARQL   Strong Buy 3 Buy 2 Hold 0 Sell 0 Strong Sell 0 Average Broker Recommendation (ABR): 1.4   ARQL Ratings: BUY  SELL  HOLD ARQL Consensus Forecasts

Rate this Stock! You haven't rated this stock yet! Ticker Call Buy Sell Analysis Time Frame Week or Less Week to a Month One to Three Months Three to Six Months Six Months to a Year One to Three Years Three Plus Years What The Community Thinks Total Players 15 Buy 0 Sell   Top Buy Analysis BUY: ARQL Company: ARQULE INC. Points: 13.71 Start Price: $5.61 Start Date: 06/06/2010 6:17 AM zorro2012 P&P Score: 98.60 Recs: Very good company with great results and bright future. Comments: 0 | Comment More Recent Analysis Top Sell Analysis No Sell Analysis. Be the First. More Recent Analysis

Blog Posts

User	User Score	Date	Title	Comments	Last Comment
Zacks_Analysts	0.00	12/14/09	Positive Results for ARRY-380 - Analyst Blog	0

Commentary

BUY: ARQULE INC. (ARQL) Start Price: $5.61 Points: +13.71 Created: 06/06/2010 Very good company with great results and bright future. Comments: 0 | Comment zorro2012 Recs:

BUY: ARQULE INC. (ARQL) Start Price: $4.23 Points: +74.73 Created: 09/15/2011 Comments: 0 | Comment sunlk8 Recs:

BUY: ARQULE INC. (ARQL) Start Price: $4.31 Points: +62.32 Created: 08/07/2011 Comments: 0 | Comment sunlk2 Recs:

BUY: ARQULE INC. (ARQL) Start Price: $6.45 Points: +15.76 Created: 06/25/2011 Comments: 0 | Comment ANTISEPTIC Recs:

BUY: ARQULE INC. (ARQL) Start Price: $7.93 Points: +7.42 Created: 01/01/2008 Comments: 0 | Comment rauli Recs:

BUY: ARQULE INC. (ARQL) Start Price: $6.02 Points: +38.98 Created: 01/01/2008 Comments: 0 | Comment cips Recs:

BUY: ARQULE INC. (ARQL) Start Price: $4.00 Points: +105.17 Created: 01/01/2008 Comments: 0 | Comment Badino Recs:

BUY: ARQULE INC. (ARQL) Start Price: $6.87 Points: +22.77 Created: 01/01/2008 Comments: 0 | Comment DARUSHNI Recs:

BUY: ARQULE INC. (ARQL) Start Price: $6.38 Points: +31.59 Created: 01/01/2008 Comments: 0 | Comment CHeetah Recs:

BUY: ARQULE INC. (ARQL) Start Price: $6.15 Points: +36.21 Created: 01/01/2008 Comments: 0 | Comment WallStreetvsMe Recs:

Pages: [ 1 ]  2  >>

Picks

Username	P&P Score	Call	Time Frame	Start Date	Start Price	Today (change)	Stock Gain	S&P Gain	Points	Analysis
sunlk8	99.76	BUY	Three to Six Months	09/15/2011	$4.23	$7.89 (-0.25%)	+86.52%	+11.79%	+74.73
sunlk2	99.79	BUY	Three to Six Months	08/07/2011	$4.31	$7.89 (-0.25%)	+83.06%	+20.74%	+62.32
ANTISEPTIC	2.54	BUY	One to Three Months	06/25/2011	$6.45	$7.89 (-0.25%)	+22.33%	+6.56%	+15.76
zorro2012	98.60	BUY	Three to Six Months	06/06/2010	$5.61	$7.89 (-0.25%)	+40.64%	+26.93%	+13.71	view close
rauli	72.43	BUY	Six Months to a Year	01/01/2008	$7.93	$7.89 (-0.25%)	-0.50%	-7.92%	+7.42
cips		BUY	Six Months to a Year	01/01/2008	$6.02	$7.89 (-0.25%)	+31.06%	-7.92%	+38.98
Badino	84.88	BUY	Six Months to a Year	01/01/2008	$4.00	$7.89 (-0.25%)	+97.25%	-7.92%	+105.17
DARUSHNI	28.75	BUY	Six Months to a Year	01/01/2008	$6.87	$7.89 (-0.25%)	+14.85%	-7.92%	+22.77
CHeetah	27.37	BUY	Six Months to a Year	01/01/2008	$6.38	$7.89 (-0.25%)	+23.67%	-7.92%	+31.59
WallStreetvsMe	72.43	BUY	Six Months to a Year	01/01/2008	$6.15	$7.89 (-0.25%)	+28.29%	-7.92%	+36.21

Pages: [ 1 ]  2  >>